GlassScriptPhysician profile
Addison Willett
NPI 1508252941
$1,171.16
in general payments reported to CMS, 2019-2025
29 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.25 · 2021: $14.19 · 2022: $85.21 · 2023: $377 · 2024: $459 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $175.17 | 2022-2025 | |
| Novocure INC. | $150.75 | 2020-2025 | Optune, Optune Gio |
| Genzyme Corporation | $72.43 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $70.03 | 2024 | Keytruda, Reblozyl |
| Janssen Biotech, INC. | $67.85 | 2022-2024 | Rybrevant, Erleada, Carvykti |
| Eisai INC. | $54.89 | 2023 | |
| Genentech USA, INC. | $44.20 | 2023 | Polivy, Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $40.78 | 2022-2024 | Fruzaqla |
| Genmab U.S., INC. | $40.51 | 2024 | Epkinly |
| Lilly USA, LLC | $39.72 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Tersera Therapeutics LLC | $35.46 | 2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $29.78 | 2025 | Libtayo |
| Reflexion Medical, INC. | $27.73 | 2022 | |
| Progenics Pharmaceuticals, INC. | $26.13 | 2023 | Pylarify |
| Invivyd INC | $24.51 | 2025 | Pemgarda |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $24.32 | 2024 | Ultomiris |
| Incyte Corporation | $24.16 | 2025 | Pemazyre, Monjuvi |
| Daiichi Sankyo INC. | $23.18 | 2024 | Enhertu |
| Karyopharm Therapeutics INC. | $22.69 | 2023 | Xpovio |
| Pharming Healthcare, INC. | $21.65 | 2023 | Ruconest |
| Siemens Medical Solutions USA, INC. | $21.51 | 2023 | Varian Ethos Treatment Planning |
| Puma Biotechnology, INC. | $20.33 | 2023 | |
| Coherus Oncology, INC. | $18.74 | 2023 | |
| Pharmacosmos Therapeutics INC. | $18.15 | 2024 | Cosela |
| Astrazeneca Pharmaceuticals LP | $16.84 | 2024 | Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $15.94 | 2024 | |
| Aveo Pharmaceuticals, INC. | $15.02 | 2022 | |
| Exelixis INC. | $14.50 | 2023 | Cabometyx |
| Amgen INC. | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Addison Willett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.